Point-of-Care Echocardiography to Assess Impact of Dynamic Cardiac Function, Renal and Cardiac Biomarkers in Cirrhosis With Refractory Ascites
Study Details
Study Description
Brief Summary
Point-of-care echocardiography (POC-Echo) is used to determine left ventricular systolic and diastolic dysfunction (LVDD), inferior vena cava (IVC) dynamics and volume status in cirrhosis and Acute-on-chronic liver failure ACLF accurately.
We will assess IVC dynamics, LV systolic function [LV ejection fraction (EF) & cardiac output (CO)], and diastolic dysfunction (E/e', e' and E/A ratio) and urinary biomarkers (cystatin C and NGAL) in patients with cirrhosis and Refractory Ascites.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
The decrease in systemic vascular resistance (SVR) and redistribution of blood volume with reduced intravascular volume compartment and third space fluid losses. Systemic vasodilatation is compensated by an increase in cardiac output (CO) in the initial stages of compensated cirrhosis. However, as the stage of liver cirrhosis progresses to decompensation, more prominent arterial vasodilatation and reduced SVR leads to a fall in CO. Thus, the cardiac homeostat is reset in a cirrhotic hyperdynamic circulation, wherein an increased heart rate, and therefore, increased cardiac output will no longer be able to compensate for the reduced mean arterial pressure (MAP), and decreased blood volumes in central venous territories.18 Consequent activation of vasoconstrictor systems including renin-angiotensin-aldosterone, vasopressin and the sympathetic nervous system comes into play to maintain the intravascular blood volume and pressure. These compensatory pathways cause an increase in sodium and water retention resulting in refractory ascites and hepatorenal syndrome (HRS). In critically ill patients with cirrhosis, the limited cardiac reserve is further stressed, CCM and heart failure may be diagnosed for the first time when the patient develops sepsis or septic shock.
Point-of-care echocardiography (POC-Echo) is used to determine left ventricular systolic and diastolic dysfunction (LVDD), inferior vena cava (IVC) dynamics and volume status in cirrhosis accurately. We will assess IVC dynamics, LV systolic function [LV ejection fraction (EF) & cardiac output (CO)], and diastolic dysfunction (E/e', e' and E/A ratio) in patients with cirrhosis ACLF and refractory ascites
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Cirrhosis with Refractory Ascites
|
Diagnostic Test: Echocardiographic assessment
POC-Echocardiography to assess dynamic changes in cardiac output to assess therapeutic responses with albumin, midodrine, diuretics and domiciliary albumin
|
Outcome Measures
Primary Outcome Measures
- Cardiac output measurement by echocardiography after albumin [Day 0]
Echocardiographic assessment of cardiac output in L/min will be recorded at least 3 time points, day 0, day 1 and day 2. The cardiac output at 3 days after enrollment and albumin therapy will also be documented. The Doppler velocity time integral (VTI) method in estimating stroke volume and cardiac output correlates well with results of concurrent thermodilution cardiac output determinations in patients without significant left-sided valvular regurgitation. Cardiac output(CO), Stroke volume (SV), Heart rate (HR) CO = [SV * HR]/ 1000
- Cardiac output measurement by echocardiography after albumin [Day 1]
Echocardiographic assessment of cardiac output in L/min will be recorded at least 3 time points, day 0, day 1 and day 2. The cardiac output at 3 days after enrollment and albumin therapy will also be documented. The Doppler velocity time integral (VTI) method in estimating stroke volume and cardiac output correlates well with results of concurrent thermodilution cardiac output determinations in patients without significant left-sided valvular regurgitation. Cardiac output(CO), Stroke volume (SV), Heart rate (HR) CO = [SV * HR]/ 1000
- Cardiac output measurement by echocardiography after albumin [Day 2]
Echocardiographic assessment of cardiac output in L/min will be recorded at least 3 time points, day 0, day 1 and day 2. The cardiac output at 3 days after enrollment and albumin therapy will also be documented. The Doppler velocity time integral (VTI) method in estimating stroke volume and cardiac output correlates well with results of concurrent thermodilution cardiac output determinations in patients without significant left-sided valvular regurgitation. Cardiac output(CO), Stroke volume (SV), Heart rate (HR) CO = [SV * HR]/ 1000
- IVC size and collapsibility changes after 20% albumin [Day 0]
IVC maximum and Minimum diameter and collapsibility index determined by percentage change in IVC diameter will be recorded.
- IVC size and collapsibility changes after 20% albumin [Day 1]
IVC maximum and Minimum diameter and collapsibility index determined by percentage change in IVC diameter will be recorded.
- IVC size and collapsibility changes after 20% albumin [Day 2]
IVC maximum and Minimum diameter and collapsibility index determined by percentage change in IVC diameter will be recorded.
- Lung Ultrasound score change after 20% Albumin [Day 0]
- Lung Ultrasound score change after 20% Albumin [Day 1]
- Lung Ultrasound score change after 20% Albumin [Day 2]
Secondary Outcome Measures
- Change in Cystatin C and Neutrophil gelatinase associated lipocalin (NGAL) level [day 0]
- Change in NT Pro brain natriuretic peptide (BNP) level [day 0]
- Change in plasma renin activity level [day 0]
- Change in Galectin-3 level [day 0]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Cirrhosis of any Etiology
-
Patient with Refractory Ascites
Exclusion Criteria:
-
Hepatocellular carcinoma
-
Patients with active variceal bleeding
-
HIV or severe immunocompromised state
-
Chronic kidney disease (CKD) on renal replacement therapy (RRT),
-
Previous transjugular intra hepatic portosystemic shunt (TIPS)
-
Porto-pulmonary hypertension,
-
Coronary artery disease
-
Congenital or valvular heart disease
-
Prosthetic cardiac valves
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | PGIMER | Chandigarh | Delhi | India | 160012 |
Sponsors and Collaborators
- Postgraduate Institute of Medical Education and Research
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
- Adebayo D, Neong SF, Wong F. Refractory Ascites in Liver Cirrhosis. Am J Gastroenterol. 2019 Jan;114(1):40-47. doi: 10.1038/s41395-018-0185-6.
- Cardenas A, Arroyo V. Refractory ascites. Dig Dis. 2005;23(1):30-8. doi: 10.1159/000084723.
- Larrue H, Vinel JP, Bureau C. Management of Severe and Refractory Ascites. Clin Liver Dis. 2021 May;25(2):431-440. doi: 10.1016/j.cld.2021.01.010. Epub 2021 Mar 11.
- Salerno F, Guevara M, Bernardi M, Moreau R, Wong F, Angeli P, Garcia-Tsao G, Lee SS. Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis. Liver Int. 2010 Aug;30(7):937-47. doi: 10.1111/j.1478-3231.2010.02272.x. Epub 2010 May 21. Erratum In: Liver Int. 2010 Sep;30(8):1244.
- NK-2020-2141